BR112013004164A2 - processo para a preparação de intermediários para a produção de inibidores da nep - Google Patents

processo para a preparação de intermediários para a produção de inibidores da nep

Info

Publication number
BR112013004164A2
BR112013004164A2 BR112013004164A BR112013004164A BR112013004164A2 BR 112013004164 A2 BR112013004164 A2 BR 112013004164A2 BR 112013004164 A BR112013004164 A BR 112013004164A BR 112013004164 A BR112013004164 A BR 112013004164A BR 112013004164 A2 BR112013004164 A2 BR 112013004164A2
Authority
BR
Brazil
Prior art keywords
production
nep inhibitors
intermediates
preparation
inhibitors
Prior art date
Application number
BR112013004164A
Other languages
English (en)
Inventor
David Hook
Jianguang Zhou
Yunzhong Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013004164A2 publication Critical patent/BR112013004164A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/12—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

processo para a preparação de intermediários para a produção de inibidores da nep. a presente invenção refere-se a um novo processo de produzir intermediários úteis para a produção de inibidores da nep ou profármacos dos mesmos, particularmente inibidores da nep compreendendo uma cadeia principal ácido y-amino-<sym>-bifenil-<244>-metilalcanoico, ou o éster do ácido tal como o éster etílico do ácido n-(3-carboxil-1-oxopropil)-(4s)-(p-fenilfenilmetil)-4-amina (2r)-metil butanoico ou sal do mesmo.
BR112013004164A 2010-08-23 2011-08-22 processo para a preparação de intermediários para a produção de inibidores da nep BR112013004164A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010076245 2010-08-23
PCT/EP2011/064410 WO2012025501A1 (en) 2010-08-23 2011-08-22 Process for the preparation of intermediates for the manufacture of nep inhibitors

Publications (1)

Publication Number Publication Date
BR112013004164A2 true BR112013004164A2 (pt) 2016-05-10

Family

ID=44658722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004164A BR112013004164A2 (pt) 2010-08-23 2011-08-22 processo para a preparação de intermediários para a produção de inibidores da nep

Country Status (14)

Country Link
US (1) US8835668B2 (pt)
EP (1) EP2609075B1 (pt)
JP (1) JP5705984B2 (pt)
KR (1) KR101476937B1 (pt)
AU (1) AU2011295170B2 (pt)
BR (1) BR112013004164A2 (pt)
CA (1) CA2806780A1 (pt)
ES (1) ES2576179T3 (pt)
MX (1) MX2013002150A (pt)
PL (1) PL2609075T3 (pt)
PT (1) PT2609075E (pt)
RU (1) RU2588572C2 (pt)
SI (1) SI2609075T1 (pt)
WO (1) WO2012025501A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
WO2016074651A1 (en) 2014-11-14 2016-05-19 Zentiva, K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
US10377697B2 (en) 2015-12-10 2019-08-13 Novartis Ag Process and intermediates
EP3386945A1 (en) 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
CN109563019A (zh) 2016-08-17 2019-04-02 诺华股份有限公司 Nep抑制剂合成的新方法和中间体
JP7138106B2 (ja) 2016-12-23 2022-09-15 ノバルティス アーゲー 初期サクビトリル中間体のための新規な方法
CN106946742A (zh) * 2017-03-28 2017-07-14 常州沃腾化工科技有限公司 一种三苯基氧磷含量低的沙库必曲中间体的制备方法
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5015793B2 (pt) 1972-06-07 1975-06-07
JPS53103412A (en) * 1977-02-18 1978-09-08 Kuraray Co Ltd Preparation of farnesyl acetic acid or its ester
US4219683A (en) * 1978-09-25 1980-08-26 Phillips Petroleum Company Isomerization of unsaturated alcohols
FR2597100A1 (fr) 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd Derives du pyroglutamide
DE3713127A1 (de) * 1987-04-16 1988-11-03 Consortium Elektrochem Ind Verfahren zur herstellung von tiglinaldehyd
JPH07103101B2 (ja) 1989-07-24 1995-11-08 キッセイ薬品工業株式会社 ピログルタミン酸誘導体
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
EP0550313A1 (fr) 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
FR2688503B1 (fr) 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
US5550119A (en) 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
KR19990082639A (ko) 1996-02-19 1999-11-25 미즈노 마사루 당뇨병 치료제
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT916656E (pt) 1997-11-14 2004-02-27 Schering Ag Metodo para producao de derivados de pirrolidinona
AU5653799A (en) 1998-09-21 2000-04-10 Takeda Chemical Industries Ltd. Novel thiol derivatives, process for producing the same and utilization thereof
CN1241909C (zh) * 2000-03-16 2006-02-15 弗·哈夫曼-拉罗切有限公司 用作ip拮抗剂的羧酸衍生物
BRPI0306907B8 (pt) 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
ES2348534T3 (es) 2002-03-29 2010-12-09 Senju Pharmaceutical Co., Ltd. Derivador de hidroximordolinona y uso medicinal del mismo.
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
JP5017098B2 (ja) 2004-05-07 2012-09-05 ユミコア・アクチエンゲゼルシャフト・ウント・コムパニー・コマンディットゲゼルシャフト 均一系のエナンチオ選択的水素化触媒のためのフェロセニル配位子
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
AR064842A1 (es) 2007-01-12 2009-04-29 Mazzucco Gavieiro Maria Belen Pirrolidin-2-onas, y su uso en la preparacion de inhibidores de nep
EP2148886B1 (en) 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
RU2564024C2 (ru) 2010-01-22 2015-09-27 Новартис Аг Промежуточные продукты для получения ингибиторов нейтральной эндопептидазы и способ их получения
BR112013004179A2 (pt) 2010-08-23 2016-05-10 Novartis Ag processo para a preparação de intermediários úteis para a fabricação de inibidores de nep

Also Published As

Publication number Publication date
US20130158285A1 (en) 2013-06-20
JP2013539462A (ja) 2013-10-24
SI2609075T1 (sl) 2016-06-30
CA2806780A1 (en) 2012-03-01
PT2609075E (pt) 2016-06-03
WO2012025501A1 (en) 2012-03-01
KR20130061735A (ko) 2013-06-11
AU2011295170A1 (en) 2013-03-21
PL2609075T3 (pl) 2016-09-30
EP2609075A1 (en) 2013-07-03
ES2576179T3 (es) 2016-07-06
EP2609075B1 (en) 2016-03-16
AU2011295170B2 (en) 2014-12-18
RU2013112946A (ru) 2014-09-27
JP5705984B2 (ja) 2015-04-22
RU2588572C2 (ru) 2016-07-10
MX2013002150A (es) 2013-04-03
KR101476937B1 (ko) 2014-12-24
US8835668B2 (en) 2014-09-16

Similar Documents

Publication Publication Date Title
BR112013004164A2 (pt) processo para a preparação de intermediários para a produção de inibidores da nep
BR112013004179A2 (pt) processo para a preparação de intermediários úteis para a fabricação de inibidores de nep
BR112015004121A2 (pt) processo
BR112012017869A2 (pt) &#34;intermediários dos inibidores da endopeptidase neutraq e método de preparação dos mesmos&#34;
CY1124919T1 (el) Κρυσταλλικη μορφη τριυδριτη toy (3s,3s&#39;) 4,4&#39;-δισουλφανοδιυλοδις(3-αμινοβουτανο 1-σουλφονικου οξεος)
EA201170955A1 (ru) Композиция растворителя
BR112012006031A2 (pt) processo para preparação de compostos azabicíclicos.
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
BR112014018756A8 (pt) Processo para preparo de etil éster de ácido n-(4-ciclo-hexil-3-trifluorometil-benziloxi)-acetimídico
BRPI1006031A2 (pt) processo de síntese de um ômega-aminoácido(éster)
MX2011004324A (es) Proceso novedoso para la preparacion de derivados de aminoacidos.
BR112012024799A2 (pt) método para a produção de l-ornitina por fermentação
BRPI0817747A8 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
EA201190306A1 (ru) Улучшенная липидная композиция
ITMI20081164A1 (it) Processo per la produzione di esteri dell&#39;acido levulinico da biomasse
CY1116498T1 (el) Διεργασια για την παρασκευη (r)-(-)-3-(καρβαμοϋλομεθυλ)-5-μεθυλεξανοϊκου οξεος και πρεγκαμπαλινης και συνθεση ενδιαμεσων
BR112014000471A2 (pt) processo para preparo de derivados de diamida de ácido antranílico substituídos com tetrazol por meio da reação de ácidos pirazóis com ésteres antranílicos
CR20120287A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112012006406A2 (pt) &#34;processo para a fabrição de n-acilbifenil alanina&#34;
BR112013030145A2 (pt) processo para preparação de ácido metacrílico
WO2014072785A8 (en) A process for the preparation of pregabalin
EA201290872A1 (ru) Способ получения бензоксаборолов
BR112014004523A2 (pt) composto e composição aromatizante
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
EA201390292A1 (ru) Ингибиторы деацетилазы на основе гидроксамата

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]